MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests A new meta-analysis by investigators from Brigham and ...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

AI enhanced MRI improves prostate cancer detection accuracy, outperforming traditional methods and supporting better diagnosis.

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

A single round of prostate cancer screening that included a prostate-specific antigen (PSA) test, a kallikrein panel, and an MRI detected one additional high-grade cancer per 196 men and one low-grade ...

An artificial intelligence system slightly outperformed radiologists using PI-RADS at detecting clinically significant prostate cancer. A trained artificial intelligence (AI) system discriminated ...

A deep learning model was as effective as radiologists in detecting clinically significant prostate cancer on multiparametric MRI, a retrospective study suggested. In an internal test set of 400 ...

There is both good news and bad news about prostate cancer screening. First, the bad news: the blood test involved, which measures a compound called prostate-specific antigen (PSA), is too inaccurate.

Lucida’s software is designed to identify prostate cancer ‘within minutes’ and overcome diagnosis delays associated with ...